Login to Your Account



Fourth Approval For Enbrel: Amgen Adds Spinal Arthritis

By Randall Osborne


Monday, July 28, 2003
As expected, Amgen Inc. and Wyeth Pharmaceuticals won marketing clearance from the FDA for Enbrel (etanercept) against ankylosing spondylitis, or arthritis of the spine. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription